top of page
Out Team
Our Research
STARLIGHT Initiative
PMAC Catalog


The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Key events and achievements

  • 10 April 2024 : Poster Presentations + Scholar-in-Training Award, AACR Annual Meeting, Florida, USA (Jing Yi Lee, Tun Kiat Ko)

  • 02 April 2024 : Collaborative research agreement with Illumina

  • 01 Nov 2023: Poster Presentation, CTOS Annual Meeting, Dublin (Elizabeth Lee)​​

  • 15 Sep 2023 : MOU and RCA signed with Agilent Technologies, BioSyngen, BGI Research and MGI Tech

  • 14 June 2023 : Poster Presentation, ICML Lugano, Switzerland

  • 14 April 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)​​

  • 20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland

  • 18 Mar 2023 : Co-organizer, Singapore Lymphoma Scientific Symposium 2023

  • 12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA​​

  • 09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)

  • 17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore​​

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea (Tun Kiat Ko)

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, US

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan (Elizabeth Lee)​​

  • 12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

Home: Services

Start a project consultation with us

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

Single-cell landscape of idiopathic multicentric Castleman disease in identical twins
Blood. 2024

May, 2024

Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine-driven disorder characterized by systemic inflammation, generalized lymphadenopathy, and organ dysfunction. Here, we present an unusual occurrence of iMCD in identical twins and examined the immune milieu within the affected lymphoid organs and the host circulation using multiomic high-dimensional profiling. Using spatial enhanced resolution omics sequencing (Stereo-seq) transcriptomic profiling, we performed unsupervised spatially constrained clustering to identify different anatomic structures, mapping the follicles and interfollicular regions. After a cell segmentation approach, interleukin 6 (IL-6) pathway genes significantly colocalized with endothelial cells and fibroblastic reticular cells, confirming observations using a single-cell sequencing approach (10× Chromium). Furthermore, single-cell sequencing of peripheral blood mononuclear cells revealed an "inflammatory" peripheral monocytosis enriched for the expression of S100A family genes in both twins. In summary, we provided evidence of the putative cell-of-origin of IL-6 signals in iMCD and described a distinct monocytic host immune response phenotype through a unique identical twin model.

Contact us

  • LinkedIn
  • Facebook
  • Instagram

Thanks for submitting!

Home: Contact
bottom of page